U.S. Respiratory Syncytial Virus Market to Witness Strong Growth from 2025 to 2032, Finds Persistence Market Research

The U.S. respiratory syncytial virus (RSV) vaccines market is entering a transformative growth phase driven by rising awareness, increasing infection rates, and expanding pharmaceutical innovation. In 2025, the market is projected to be valued at US$ 604.8 million, and is expected to grow at a compelling CAGR of 15.6% to reach US$ 1,667.8 million by 2032. This fast-paced growth reflects a significant surge in the demand for RSV prophylaxis and therapeutic interventions, especially among vulnerable populations such as infants and the elderly.

One of the major growth drivers for the market is the rising prevalence of RSV-associated lower respiratory tract infections. Among various product segments, Arexvy (RSVPreF3 OA) by GSK is expected to dominate, thanks to its high efficacy rate of 94% and rapid adoption since its launch in 2023. In terms of geography, the Northeast region of the U.S. leads the market due to higher hospitalization rates associated with RSV, robust healthcare infrastructure, and proactive immunization programs targeting older adults.

✅Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/33045

Key Highlights from the Report

✦ The U.S. RSV vaccines market is set to grow at a 15.6% CAGR from 2025 to 2032.
✦ Market valuation is forecasted to reach US$ 1,667.8 Mn by the end of 2032.
✦ Arexvy by GSK has achieved over 9 million administered doses since its launch.
✦ Institutional sales remain the dominant distribution channel, expanding at a 13.7% CAGR.
✦ RSV is responsible for 177,000 hospitalizations and 14,000 deaths annually among U.S. seniors.
✦ FDA approvals of mRESVIA and ABRYSVO enhance market competitiveness.

Market Segmentation

The U.S. respiratory syncytial virus vaccines market is segmented by drug type and distribution channel. Among drug types, monoclonal antibodies such as Palivizumab and Nirsevimab are extensively used to treat RSV-related infections, especially in premature infants and older adults. Recent approvals, such as Moderna's mRESVIA and Pfizer's ABRYSVO, are pushing the envelope in terms of innovation and reach.

The distribution channel segment highlights that institutional sales lead the market. Research institutions and hospitals account for a substantial share of RSV vaccine distribution. Their role in clinical trials, academic research, and collaborative public-private partnerships has made institutional sales a backbone of the RSV vaccine supply chain.

Regional Insights

Regionally, the Northeast United States dominates the RSV vaccines market, driven by high RSV-related hospitalization rates, strong state-level healthcare policies, and early adoption of preventive immunization strategies. The Midwest is emerging as a strong contender, supported by growing awareness campaigns and enhanced federal support. Meanwhile, Southern and Western U.S. regions are catching up, fueled by rising RSV cases and increased access to vaccines through community health initiatives and pharmacy chains.

Market Drivers

One of the primary drivers of the U.S. RSV vaccines market is the increasing rate of premature births, which raises the risk of RSV-related complications. Additionally, a robust product pipeline featuring vaccines in various clinical phases-such as subunit, live-attenuated, and vector-based vaccines-fuels market dynamism. The growing adoption of online platforms has also enabled widespread dissemination and access to RSV vaccines, especially for adults over 60, the age group most affected by RSV.

Market Restraints

Despite impressive advancements, the high cost of RSV vaccine development and treatment acts as a significant constraint. Development and production of biologics like Palivizumab are expensive, and new entrants like Nirsevimab, although more affordable, still present affordability challenges for many patients. Additionally, many vaccine candidates have failed in late-stage clinical trials, which increases developmental costs and delays new product launches.

✅Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/33045

Market Opportunities

The U.S. market is poised for growth thanks to government funding, public-private collaborations, and regulatory incentives aimed at enhancing vaccine R&D. The FDA's expedited approval process, particularly for high-risk populations, offers manufacturers a smoother path to market entry. Furthermore, technological advancements such as mRNA-based vaccines are paving the way for more cost-effective and potent treatment options. The expansion of coverage to younger adults (50-59 years) also opens up new demographic segments for vaccine manufacturers.

Reasons to Buy the Report

✔ Gain comprehensive insights into market trends, drivers, and forecasts through 2032.
✔ Access detailed competitive intelligence on leading players and their market strategies.
✔ Identify high-growth segments and investment pockets based on robust segmentation.
✔ Leverage expert analysis of regulatory changes and their impact on market dynamics.
✔ Understand pricing trends and cost-efficiency strategies adopted by industry leaders.

Company Insights

The U.S. respiratory syncytial virus vaccines market is characterized by intense competition, technological innovation, and strategic partnerships. Key players operating in the market include:

• Pfizer Inc.
• Sanofi
• Merck Sharp & Dohme
• GlaxoSmithKline
• SOBI
• Johnson & Johnson
• Bavarian Nordic
• Novavax
• AstraZeneca
• Moderna, Inc.
• Codagenix Inc.
• Intravacc BV.
• Alphavax, Inc.

Recent Developments

• In April 2025, the CDC's Advisory Committee approved Pfizer's ABRYSVO for high-risk adults aged 50-59.
• In April 2024, Sanofi increased the price of Nirsevimab to US$ 519.75 per dose, highlighting cost-based market dynamics.

Conclusion

The U.S. respiratory syncytial virus vaccines market is undergoing a period of dynamic expansion fueled by medical innovation, rising infection rates, and robust government support. With a market value expected to nearly triple by 2032, key stakeholders-including pharmaceutical giants, healthcare providers, and federal agencies-are investing heavily in R&D, vaccine deployment, and accessibility initiatives. While high development costs remain a barrier, the emergence of cost-effective alternatives and expanded patient eligibility are reshaping the landscape. As the burden of RSV grows more acute, especially among infants and the elderly, the U.S. market is poised to lead global RSV vaccine innovation and implementation.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.